FreshLeaf Analytics has released this interesting, in-depth analysis of the patients, products and pricing of the Australian cannabis industry.
“While patient numbers have continued to accelerate at break-neck speed, there are several factors holding the industry back, chief among them being the lack of governmental subsidization via the Pharmaceutical Benefits Scheme.
Australia’s tough driving regulations—which take a strict no-tolerance stance on THC—were also singled out by the report as another key issue that is impeding further growth.
According to the report, if current patient approval trends continue then the Australia medicinal cannabis industry can be expected to grow to approximately $50 million of annualized revenue by the end of the year.”
Read the full report here at The Green Fund:
FreshLeaf Analytics Publishes “Most Comprehensive” Study of Australian Cannabis Market | The Green Fund